Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Cambridge, Mass.-based Moderna (MRNA) had a net profit of $13 million, or 3 cents a share, for the quarter, after a loss of $3.6 billion, or $9.53 a share, in the year-earlier period. Revenue rose to ...

Norovirus is a very contagious virus that causes vomiting and diarrhoea. Credit: New Africa via Shutterstock. A Phase III clinical trial is being launched in the UK to investigate Moderna’s norovirus ...

Its mRNA-1273 vaccine, known as Spikevax, remains crucial in combating COVID-19. During the second quarter of fiscal 2024, the company launched its RSV vaccine, branded as mRESVIA, in the United ...

The study, published in ACS Nano, analysed more than 150 blood samples taken from 19 people in the 28 days after they received the Moderna SPIKEVAX mRNA booster. It also uncovered another key ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to mRNA technology in Moderna's COVID-19 vaccine Spikevax and RSV shot mResvia.

Moderna earned US$6.7 billion (S$8.7 billion) in revenue from Spikevax last year. Pfizer made US$11.2 billion from sales of Comirnaty, the Covid vaccine it developed with German partner BioNTech.

GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its patented mRNA technology in their Spikevax COVID-19 vaccine without ...

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of its and BioNTech's vaccine Comirnaty. Sales of both vaccines declined significantly last ...